Viewing nowRovacan Tablets 5mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Seoheung Co., Ltd.

MFDS item code 201906608 · Approved 2019.09.23 · Insurance code 679601230
Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease
This drug is primarily used as an adjunct in patients with primary hypercholesterolemia and mixed dyslipidemia when dietary changes and exercise are not enough to control their condition. It is also used as an adjunct in the treatment of homozygous familial hypercholesterolemia. It effectively lowers total cholesterol and LDL cholesterol levels to delay the progression of atherosclerosis in patients with hypercholesterolemia. It is also used as an adjunct to diet in pediatric patients with familial hypercholesterolemia aged 10 to 17 years. It helps in the treatment of primary dysbetalipoproteinemia patients. Additionally, it reduces the risk of stroke, myocardial infarction, and arterial revascularization procedures in certain high-risk patients, thus decreasing the overall risk of cardiovascular disease. Therefore, this drug is used to improve the risks associated with dyslipidemia and cardiovascular diseases.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults : No dose adjustment is required. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Aged 10 years to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) Under 10 years: Safety and efficacy have not been established.
This drug should not be used in certain patients. For example, it should not be administered to patients with hypersensitivity to this drug, those with active liver disease, myopathy patients, and those with severe renal impairment. Pregnant or breastfeeding women should not use this drug, and women of childbearing age should use appropriate contraceptive methods. High-dose administration is contraindicated in patients at high risk of muscle-related disorders or those with a history of certain genetic muscle diseases, and these patients should be treated with caution. This drug contains lactose, so patients with lactose intolerance should not take it. Patients who consume excessive amounts of alcohol or have a history of liver disease should undergo regular liver function tests before and during treatment with this drug. If symptoms of muscle pain or weakness occur, inform medical staff immediately and check for muscle damage through blood tests if necessary. Treatment should be discontinued if acute renal failure or severe metabolic disorders occur during the use of this drug. Particularly, elderly patients, those with renal impairment, and patients with hypothyroidism, who are at higher risk of muscle damage, should be closely monitored. This drug may interact with other medications, so inform healthcare staff of any medications currently being taken and discuss dosage adjustments or co-administration. Its safety during pregnancy has not been established, so it should not be used during pregnancy or while breastfeeding. In case of overdose, as there is no specific antidote, immediate medical treatment and monitoring should be obtained. Caution is advised while driving or operating machinery, as dizziness may occur. Rarely, during the use of this drug, serious skin reactions, liver function abnormalities, muscle damage, and other adverse effects may occur; therefore, contact medical staff immediately if abnormal symptoms appear.
Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, difficulty breathing, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, dysesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container, avoiding exposure to air or moisture, and ideally at room temperature between 1 degree and 30 degrees Celsius. This storage ensures the drug's effectiveness and safety.
Yellow round film-coated tablets
28 tablets (14 tablets/PTP X 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Seoheung Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.